Effects of delta-sleep-inducing peptide in cerebral ischemia in rats.
Shandra. A A AA; Godlevskii. L S LS; Brusentsov. A I AI; Vast'yanov. R S RS; Karlyuga. V A VA; Dzygal. A F AF; Nikel. B B
Key Findings
- DSIP reduced postural (movement) abnormalities in rats with induced cerebral ischemia.
- DSIP lowered the death rate of these rats within 24 hours of the injury.
- DSIP showed greater neuroprotective effect than the NMDA antagonist MK‑801 in this model.
Practical Outcomes
- The study suggests DSIP might have brain‑protective properties that could one day be useful for stroke or neuro‑injury prevention, but there is no human data, dosing guidance, or safety profile yet. For now, it remains a pre‑clinical finding and isn’t ready for self‑experimentation or clinical use.
Summary
In a rat study, a peptide called delta‑sleep‑inducing peptide (DSIP) helped protect the brain after a stroke‑like injury. The treated rats showed fewer movement problems and fewer deaths within a day, and DSIP worked even better than a known neuroprotective drug (MK‑801). The researchers think this could point to DSIP as a future stroke treatment, but it’s still early‑stage animal work.
Abstract
Experimental studies were carried out to investigate the neuroprotective effects of delta sleep-inducing peptide in animals with cerebral ischemia induced by bilateral compression of both carotid arteries, and to compare the efficacy of this peptide with that of MK-801. These studies led to the conclusion that the peptide had pronounced anti-ischemic effects, which were evident within 24 h and consisted of reductions in the severity of postural abnormalities in rats with bilateral cerebral ischemia, along with a reduction in lethality. Comparison of the efficacies of peptide and MK-801 showed the peptide to have the greater neuroprotective effect. These results are regarded as providing an experimental basis for using the peptide as a therapeutic agent in patients with stroke.
Study Information
pubmed
1998
10.1007/bf02464804